TransCode Therapeutics appoints Jack Stover to board of directors

TransCode Therapeutics Inc. (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its board of directors. Stover will join the audit and nominating committees as Dr. Magda Marquet steps down from the audit committee.

Stover brings more than 30 years of executive leadership experience across public and private life sciences companies in drug development, diagnostics, specialty pharmaceuticals and capital formation, according to the company's statement.

Stover currently serves as chairman of the board of Traws Pharma Inc., a specialty pharmaceutical company focused on anti-virals and oncology. He led the merger of Traws with Onconova Therapeutics Inc. and served as director and chairman of the audit committee of Onconova since 2016.

From March 2021 until July 2025, Stover served as CEO and director of NorthView Acquisition Corp., a special purpose acquisition corporation. He subsequently became a director of Profusa Inc., a digital health company developing tissue integrated biosensors that merged with NVAC.

From June 2016 through December 2020, Stover served as president, CEO and director of Interpace Biosciences Inc., a molecular diagnostics company in oncology. During his tenure, he led the acquisition of Cancer Genetics and executed multiple financings.

From 2004 to 2008, Stover was CEO and director of Antares Pharma Inc., a specialty pharmaceutical company. He led the integration of disposable injectables with proprietary therapeutics that resulted in the sale of Antares to Halozyme for more than $900 million.

Stover was previously a partner with PricewaterhouseCoopers, where he led the life science industry practice in the Mid-Atlantic region.

TransCode Therapeutics is a clinical stage company developing immuno-oncology and RNA treatments for high risk and advanced cancer.

You May Also Be Interested In

• Onconetix advances $500K more to Realbotix, total now $3M
• Takeda's TAK-921 meets dual endpoints in gastric cancer trial
• Founder Group regains Nasdaq compliance on publicly held shares